ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement to share for editorial consideration in DCAT Value Chain Insights? Click here to submit.
* Bespak Submits Greenhouse Gas Reduction Targets to SBTi
* PCI Pharma Services Receives SBTi Validation for Greenhouse Gas Reduction Targets
* Piramal Releases Sustainability Report
Bespak Submits Greenhouse Gas Reduction Targets to SBTi
Bespak, a specialist inhalation CDMO, has submitted net-zero and near-term company-wide emission reduction targets to the Science Based Targets initiative (SBTi), an internationally recognized organization that supports companies in developing science-based climate goals. Science-based targets offer companies a path to align emission reductions with the Paris Agreement goals, which seek to limit global warming to 1.5 °C. Bespak has submitted its Scope 1 and 2 emission reduction targets to the SBTi alongside its Scope 3 near- and long-term targets, which are based on an economic intensity reduction, with a near-term target year of 2033 and long-term target year of 2050. Bespak aims to reduce emissions in the most emission-intensive areas of its footprint, such as the use-phase of sold products, purchase of capital goods & services, and upstream transportation and distribution. As a next step, SBTi will now assess and validate Bespak’s science-based targets against the SBTi’s criteria.
Source: Bespak
PCI Pharma Services Receives SBTi Validation for Greenhouse Gas Reduction Targets
PCI Pharma Services has received validation from the Science Based Targets initiative (SBTi) for its near-term and net-zero greenhouse gas (GHG) reduction targets. Specifically, PCI has committed to achieving the following science-based targets that would in the near-term, per its SBTi approved targets, to nearly halve its direct (Scope 1) emissions by 2030. In this same timeframe, the company aims to reduce by nearly half its indirect Scope 2 emissions from purchased electricity, heating, and cooling. Additionally, PCI is targeting a 25% reduction in its Scope 3 emissions, which involves partners and vendors along its value chain.
Its specific near-term targets are to reduce absolute Scope 1 and 2 GHG emissions 48% by FY 2030 from a FY 2023 base year and reduce absolute Scope 3 GHG emissions 25% by FY 2030 from a FY 2024 base year. For long-term targets, the company plans to reduce absolute Scope 1 and 2 GHG emissions 90% by FY 2040 from a FY 2023 base year and reduce absolute Scope 3 GHG emissions 90% by FY 2045 from a FY 2024 base year. Its net-zero target is to reach net-zero GHG emissions across its value chain by FY 2045.
Source: PCI Pharma Services
Piramal Releases Sustainability Report
Piramal Pharma Limited (PPL) has released its fourth annual Sustainability Report for the financial year 2025. The report outlines measurable progress and strengthened commitments under its four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. The report highlights how PPL is embedding responsible practices across its global operations from strengthening governance and ethics to accelerating climate action, advancing diversity and inclusion, and driving social impact through partnerships.
In highlighting decarbonization milestones, the company reported the following: (1) a 6% reduction in Scope 1 & 2 emissions (year over year); (2) a 7.8% increase in renewable energy use, with 20.2% of total energy from bioenergy; (3) zero hazardous waste to landfill and a target of 90% recycling of non-hazardous waste; (4) 2.10 lakh kiloliters of freshwater saved through integrated water stewardship; (5) biodiversity initiatives that included plantation of 2,000+ saplings and maintaining 30% green cover across its sites in India; and (6) undertaking a significant project at PPL’s Digwal, India, facility by converting its coal-fired steam boiler to run on renewable biomass briquettes.
Source: Piramal Pharma
